These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1139 related items for PubMed ID: 29661141

  • 21. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T, Borges K, Williams A, Banh T, Vasilevska-Ristovska J, Allen U, Parekh RS, Hébert D.
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [Abstract] [Full Text] [Related]

  • 22. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
    Halleck F, Khadzhynov D, Schrezenmeier E, Lehner L, Budde K, Staeck O.
    Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
    [Abstract] [Full Text] [Related]

  • 23. Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.
    Tarasewicz A, Dębska-Ślizień A, Rutkowski B.
    Transplant Proc; 2016 Jun; 48(5):1650-3. PubMed ID: 27496465
    [Abstract] [Full Text] [Related]

  • 24. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
    Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA.
    JAMA; 2023 Jul 03; 330(1):33-42. PubMed ID: 37279999
    [Abstract] [Full Text] [Related]

  • 25. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.
    Transplantation; 1998 Dec 27; 66(12):1682-8. PubMed ID: 9884259
    [Abstract] [Full Text] [Related]

  • 26. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
    Luan FL, Samaniego M, Kommareddi M, Park JM, Ojo AO.
    Transpl Infect Dis; 2010 Dec 27; 12(6):473-9. PubMed ID: 20576019
    [Abstract] [Full Text] [Related]

  • 27. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
    Lee H, Park KH, Ryu JH, Choi AR, Yu JH, Lim J, Han K, Kim SI, Yang CW, Chung BH, Oh EJ.
    PLoS One; 2017 Dec 27; 12(12):e0189488. PubMed ID: 29232714
    [Abstract] [Full Text] [Related]

  • 28. A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation.
    Westall GP, Cristiano Y, Levvey BJ, Whitford H, Paraskeva MA, Paul E, Peleg AY, Snell GI.
    Transplantation; 2019 May 27; 103(5):1005-1013. PubMed ID: 30247316
    [Abstract] [Full Text] [Related]

  • 29. Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients.
    Imlay H, Dumitriu Carcoana AO, Fisher CE, Wong B, Rakita RM, Fishbein DP, Limaye AP.
    Transpl Infect Dis; 2020 Jun 27; 22(3):e13255. PubMed ID: 32020736
    [Abstract] [Full Text] [Related]

  • 30. Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.
    Andreani M, Albano L, Benzaken S, Cassuto E, Jeribi A, Caramella A, Giordanengo V, Bernard G, Esnault V, Seitz-Polski B.
    Transplant Proc; 2020 Jun 27; 52(1):204-211. PubMed ID: 31889538
    [Abstract] [Full Text] [Related]

  • 31. Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir.
    Nanmoku K, Shinzato T, Kubo T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2018 Jun 27; 50(1):124-129. PubMed ID: 29407294
    [Abstract] [Full Text] [Related]

  • 32. Comparison of the T-cell response to human cytomegalovirus (HCMV) as detected by cytokine flow cytometry and QuantiFERON-CMV assay in HCMV-seropositive kidney transplant recipients.
    Gabanti E, Lilleri D, Scaramuzzi L, Zelini P, Rampino T, Gerna G.
    New Microbiol; 2018 Jul 27; 41(3):195-202. PubMed ID: 30028473
    [Abstract] [Full Text] [Related]

  • 33. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA, Angarone MP, Rich JD, Anderson AS, Stosor V.
    Transpl Infect Dis; 2018 Aug 27; 20(4):e12896. PubMed ID: 29602266
    [Abstract] [Full Text] [Related]

  • 34. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J, Hatakeyama S, Wakai S, Omoto K, Okumi M, Tanabe K, Mieno M, Shirakawa H.
    Int J Infect Dis; 2017 Dec 27; 65():50-56. PubMed ID: 28986314
    [Abstract] [Full Text] [Related]

  • 35. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
    Witzke O, Nitschke M, Bartels M, Wolters H, Wolf G, Reinke P, Hauser IA, Alshuth U, Kliem V.
    Transplantation; 2018 May 27; 102(5):876-882. PubMed ID: 29166336
    [Abstract] [Full Text] [Related]

  • 36. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
    Abate D, Saldan A, Mengoli C, Fiscon M, Silvestre C, Fallico L, Peracchi M, Furian L, Cusinato R, Bonfante L, Rossi B, Marchini F, Sgarabotto D, Rigotti P, Palù G.
    J Clin Microbiol; 2013 Aug 27; 51(8):2501-7. PubMed ID: 23678073
    [Abstract] [Full Text] [Related]

  • 37. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.
    Transplant Proc; 2005 Sep 27; 37(7):3182-6. PubMed ID: 16213344
    [Abstract] [Full Text] [Related]

  • 38. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H, Mutlu E, Köksoy S, Yılmaz VT, Koçak H, Çolak D, Mutlu D, Günseren F, Dinçkan A, Aliosmanoğlu İ, Süleymanlar G, Gültekin M.
    Mikrobiyol Bul; 2016 Apr 27; 50(2):224-35. PubMed ID: 27175495
    [Abstract] [Full Text] [Related]

  • 39. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K, Mitro G, Buschor K, Rees M, Ortiz J.
    Transpl Immunol; 2019 Oct 27; 56():101226. PubMed ID: 31344441
    [Abstract] [Full Text] [Related]

  • 40. Cytomegalovirus infection in high-risk kidney transplant recipients receiving thymoglobulin induction-a single-center experience.
    Puttarajappa C, Bhattarai M, Mour G, Shen C, Sood P, Mehta R, Shah N, Tevar AD, Humar A, Wu C, Hariharan S.
    Clin Transplant; 2016 Sep 27; 30(9):1159-64. PubMed ID: 27423138
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.